tiprankstipranks
Wells bullish on Travere Therapeutics, sees 30% of upside on submission plans
PremiumThe FlyWells bullish on Travere Therapeutics, sees 30% of upside on submission plans
6d ago
Travere Therapeutics to submit sNDA for FILSPARI in FSGS
Premium
The Fly
Travere Therapeutics to submit sNDA for FILSPARI in FSGS
6d ago
Promising Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Financial Strength
Premium
Ratings
Promising Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Financial Strength
14d ago
Travere Therapeutics sees FY24 net product sales approx $227M
PremiumThe FlyTravere Therapeutics sees FY24 net product sales approx $227M
1M ago
MHRA approves Travere’s sparsentan to treat adults with primary IgAN
Premium
The Fly
MHRA approves Travere’s sparsentan to treat adults with primary IgAN
3M ago
Travere Therapeutics price target raised to $22 from $12 at Piper Sandler
Premium
The Fly
Travere Therapeutics price target raised to $22 from $12 at Piper Sandler
3M ago
Travere Therapeutics Boosts Sales with FILSPARI Approval
PremiumCompany AnnouncementsTravere Therapeutics Boosts Sales with FILSPARI Approval
4M ago
Travere Therapeutics reports Q3 adjusted EPS (46c), consensus (68c)
Premium
The Fly
Travere Therapeutics reports Q3 adjusted EPS (46c), consensus (68c)
4M ago
Travere presents data reinforcing clinical benefit of FILSPARI in IgAN
Premium
The Fly
Travere presents data reinforcing clinical benefit of FILSPARI in IgAN
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100